News

European Patent Office Grants Further Patent to Salipro Biotech

February 10, 2022

The European Patent Office has granted another patent to Salipro Biotech, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

CGT Catapult Partners with MICA Biosystems

February 10, 2022

CGT Catapult has partnered with MICA Biosystems to advance MICA’s regenerative medicine technology to the UK’s MHRA.

FDA Faces Huge Task Catching Up on Inspections

February 08, 2022

With new COVID-19 infections declining, the agency is resuming domestic inspections of drug manufacturing facilities.

Synaffix Inks $586 Million Deal with MacroGenics to Enable Next Generation ADCs

February 08, 2022

MacroGenics will use Synaffix’s technology to investigate next-generation ADCs.

Intellia Therapeutics Acquires Rewrite Therapeutics

February 07, 2022

The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.

FDA Approves Bispecific Antibody to Treat Vision Loss

February 07, 2022

The agency approved Roche’s Vabysmo to treat neovascular or “wet” age-related macular degeneration and diabetic macular edema.

Bio-Rad Launches Anti-Pertuzumab Antibodies

February 07, 2022

Bio-Rad’s four new antibodies will develop highly selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.

Gandeeva Raises $40M to Develop Novel Therapies Based on Precision Imaging of Protein-Drug Interactions

February 07, 2022

Gandeeva raisded $40 million to advance its AI-driven cryo-EM platform, with which it will develop new therapeutics based on the precise imaging of protein–drug interactions.

Politics Impact FDA

February 07, 2022

A range of political issues have impacted FDA initiatives vital to the agency’s effectiveness and stature, both at home and on the important global stage.

Domainex Collaborates with UK Charity to Develop Therapies for Parkinson’s

February 04, 2022

Domainex is collaborating with Parkinson’s UK for the development of small-molecule therapies targeting the neuroinflammation that is associated with Parkinson’s disease.